Akari Therapeutics, Plc
AKTX
$11.04
$0.080.73%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -152.38% | -56.43% | 12.60% | 21.75% | 39.07% |
| Total Depreciation and Amortization | -- | -- | -- | -92.86% | -93.33% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 9,173.79% | 879.92% | 939.94% | 4,174.36% | -65.72% |
| Change in Net Operating Assets | -63.91% | -102.43% | -106.18% | -78.44% | -18.30% |
| Cash from Operations | -19.28% | -2.33% | 15.81% | 34.95% | 42.90% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | 109.90% | 109.90% | 110.11% | -100.00% |
| Total Debt Repaid | 67.50% | 68.76% | 43.29% | -115.76% | -273.08% |
| Issuance of Common Stock | 46.83% | -35.51% | -9.97% | -26.76% | -26.76% |
| Repurchase of Common Stock | -- | -- | -- | -- | -10,600.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 213.94% | -- | -- | -- | -- |
| Cash from Financing | 117.92% | -4.45% | 19.87% | -22.56% | -43.53% |
| Foreign Exchange rate Adjustments | -142.86% | 0.00% | 125.00% | 100.00% | 450.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 454.41% | -86.04% | 319.56% | 111.99% | 53.20% |